Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03333746 · MORE INFO

Limitations, agreements, and source contact

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2019-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Study was discontinued due to FDA recommendations of the potential toxities of the combination of nivolumab with an immunemodulator(lenalidomide, pomalidomde)
point Of Contact
email
Yvonne.Efebera@osumc.edu
organization
The Ohio State University Comprehensive Cancer Center
phone
614-293-7243
phone Ext
1278
title
Dr. Yvonne Efebera
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Study was discontinued due to FDA recommendations of the potential toxities of the combination of nivolumab with an immunemodulator(lenalidomide, pomalidomde)
point Of Contact
email
Yvonne.Efebera@osumc.edu
organization
The Ohio State University Comprehensive Cancer Center
phone
614-293-7243
phone Ext
1278
title
Dr. Yvonne Efebera

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice